CoChat
Sign Up
Cited by 80

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

MicroRNAs in IgA nephropathy

Szeto, Cheuk-Chun, Li, Philip K.-T.·2014·Nature Reviews Nephrology
DOI 10.1038/nrneph.2014.50
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrneph.2014.50

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 73

  1. Li, P. K., Ho, K. K., Szeto, C. C., Yu, L. & Lai, F. M. Prognostic indicators of IgA nephropathy in the Chinese—clinical and pathological perspectives. Nephrol. Dial. Transplant. 17, 64–69 (2002). · DOI
  2. Le, W. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 27, 1479–1485 (2012). · DOI
  3. Zuo, L. & Wang, M. Current burden and probable increasing incidence of ESRD in China. Clin. Nephrol. 74 (Suppl. 1), S20–S22 (2010).
  4. Schena, F. P. & Coppo, R. in Oxford Textbook of Clinical Nephrology 3rd edn (eds Davison, A. M. et al.) 469–501 (Oxford University Press, 2005).
  5. Ho, Y.-W. et al. Hong Kong Renal Registry Report 2010. Hong Kong J. Nephrol. 12, 81–98 (2010). · DOI
  6. Knoop, T. et al. Mortality in patients with IgA nephropathy. Am. J. Kidney Dis. 62, 883–890 (2013). · DOI
  7. Novak, J., Renfrow, M. B., Gharavi, A. G. & Julian, B. A. Pathogenesis of immunoglobulin A nephropathy. Curr. Opin. Nephrol. Hypertens. 22, 287–294 (2013). · DOI
  8. Roos, A. & van Kooten, C. Underglycosylation of IgA in IgA nephropathy: more than a diagnostic marker? Kidney Int. 71, 1089–1091 (2007). · DOI
  9. Boyd, J. K., Cheung, C. K., Molyneux, K., Feehally, J. & Barratt, J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 81, 833–843 (2012). · DOI
  10. Moldoveanu, Z. et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71, 1148–1154 (2007). · DOI
  11. Smith, A. C., Molyneux, K., Feehally, J. & Barratt, J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J. Am. Soc. Nephrol. 17, 3520–3528 (2006). · DOI
  12. Li, G. S., Zhang, H., Lv, J. C., Shen, Y. & Wang, H. Y. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 71, 448–453 (2007). · DOI
  13. Serino, G., Sallustio, F., Cox, S. N., Pesce, F. & Schena, F. P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J. Am. Soc. Nephrol. 23, 814–824 (2012). · DOI
  14. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343–349 (2004). · DOI
  15. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116, 281–297 (2004). · DOI
  16. Morita, K. & Han, M. Multiple mechanisms are involved in regulating the expression of the developmental timing regulator lin-28 in Caenorhabditis elegans. EMBO J. 25, 5794–5804 (2006). · DOI
  17. Chan, S. P., Ramaswamy, G., Choi, E. Y. & Slack, F. J. Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans. RNA 14, 2104–2114 (2008). · DOI
  18. Bernstein, E. et al. Dicer is essential for mouse development. Nat. Genet. 35, 215–217 (2003). · DOI · Paper page
  19. Bartels, C. L. & Tsongalis, G. J. MicroRNAs, novel biomarkers for human cancer. Clin. Chem. 55, 623–631 (2009). · DOI
  20. Xiao, C. & Rajewsky, K. MicroRNA control in the immune system, basic principles. Cell 136, 26–36 (2009). · DOI
  21. Tian, Z., Greene, A. S., Pietrusz, J. L., Matus, I. R. & Liang, M. MicroRNA–target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18, 404–411 (2008). · DOI
  22. Sun, Y. et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32, e188 (2004). · DOI
  23. Gregory, P. A., Bracken, C. P., Bert, A. G. & Goodall, G. J. MicroRNAs as regulators of epithelial–mesenchymal transition. Cell Cycle 7, 3112–3118 (2008). · DOI
  24. Neilson, E. G. Mechanisms of disease: fibroblasts—a new look at an old problem. Nat. Clin. Pract. Nephrol. 2, 101–108 (2006). · DOI
  25. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582–589 (2008). · DOI
  26. Park, S.-M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894–907 (2008). · DOI · Paper page
  27. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910–14914 (2008). · DOI
  28. Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial–mesenchymal transition. Cancer Res. 68, 7846–7854 (2008). · DOI
  29. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593–601 (2008). · DOI
  30. Lorenzen, J. M., Haller, H. & Thum, T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat. Rev. Nephrol. 7, 286–294 (2011). · DOI
  31. Chandrasekaran, K. et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int. 81, 617–627 (2012). · DOI
  32. Tan, K. et al. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome 56, 161–169 (2013). · DOI
  33. Tanzer, A. & Stadler, P. F. Molecular evolution of a microRNA cluster. J. Mol. Biol. 339, 327–335 (2004). · DOI
  34. Serva, A. et al. miR-17-5p regulates endocytic trafficking through targeting TBC1D2/Armus. PLoS ONE 7, e52555 (2012). · DOI
  35. Dong, Y. et al. Tumor suppressor functions of miR-133a in colorectal cancer. Mol. Cancer Res. 11, 1051–1060 (2013). · DOI
  36. Liu, W. et al. miR-133a regulates adipocyte browning in vivo. PLoS Genet. 9, e1003626 (2013). · DOI
  37. Wang, J. et al. Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition. Cell Death Dis. 4, e699 (2013). · DOI
  38. Silva, F. G., Chander, P., Pirani, C. L. & Hardy, M. A. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33, 241–246 (1982).
  39. Chen, Y, Song, Y. X. & Wang, Z. N. The microRNA-148/152 family, multi-faceted players. Mol. Cancer 12, 43 (2013). · DOI
  40. Liu, X. et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIα. J. Immunol. 185, 7244–7251 (2010). · DOI
  41. Cimino, D. et al. miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 27, 1223–1235 (2013). · DOI
  42. Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7, e38248 (2012). · DOI
  43. Cao, J. et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73, 3326–3335 (2013). · DOI
  44. Floege, J. The pathogenesis of IgA nephropathy, what is new and how does it change therapeutic approaches? Am. J. Kidney Dis. 58, 992–1004 (2011). · DOI
  45. Loeffler, I. & Wolf, G. Transforming growth factor-β and the progression of renal disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i37–i45 (2014). · DOI
  46. Liu, Y. et al. Renal medullary microRNAs in Dahl salt-sensitive rats, miR-29b regulates several collagens and related genes. Hypertension 55, 974–982 (2010). · DOI
  47. Qin, W. et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462–1474 (2011). · DOI
  48. Fang, Y. et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am. J. Physiol. Renal Physiol. 304, F1274–F1282 (2013). · DOI
  49. Wang, G. et al. Intra-renal expression of microRNAs in patients with IgA nephropathy. Lab. Invest. 90, 98–103 (2010). · DOI
  50. Wang, G. et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30, 171–179 (2011). · DOI · Paper page
  51. Puhr, M. et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 181, 2188–2201 (2012). · DOI
  52. Muratsu-Ikeda, S. et al. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS ONE 7, e41462 (2012). · DOI
  53. Yang, L. et al. miR-146a controls the resolution of T cell responses in mice. J. Exp. Med. 209, 1655–1670 (2012). · DOI
  54. Ichii, O. et al. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int. 81, 280–292 (2012). · DOI
  55. Vigorito, E., Kohlhaas, S., Lu, D. & Leyland, R. miR-155, an ancient regulator of the immune system. Immunol. Rev. 253, 146–157 (2013). · DOI
  56. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra128 (2012). · DOI
  57. Chung, A. C., Huang, X. R., Meng, X. & Lan, H. Y. miR-192 mediates TGF-β/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21, 1317–1325 (2010). · DOI
  58. Krupa, A., Jenkins, R., Luo, D. D., Lewis, A., Phillips, A. & Fraser, D. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 438–447 (2010). · DOI
  59. Du, B. et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584, 811–816 (2010). · DOI
  60. Wang, Q. et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22, 4126–4135 (2008). · DOI
  61. Fleissner, F. et al. Short communication, asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ. Res. 107, 138–143 (2010). · DOI
  62. Hanke, M. et al. A robust methodology to study urine microRNA as tumor marker, microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28, 655–661 (2010). · DOI
  63. Cortez, M. A. & Calin, G. A. MicroRNA identification in plasma and serum, a new tool to diagnose and monitor diseases. Expert Opin. Biol. Ther. 9, 703–711 (2009). · DOI
  64. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008). · DOI · Paper page
  65. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008). · DOI
  66. Lorenzen, J. M. et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am. J. Transplant. 11, 2221–2227 (2011). · DOI
  67. Wang, G. et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20, 493–500 (2011). · DOI
  68. Wang, G. & Szeto, C. C. Methods of microRNA quantification in urinary sediment. Methods Mol. Biol. 1024, 211–220 (2013). · DOI
  69. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223–7233 (2011). · DOI · Paper page
  70. Wang, G. et al. Serum and urinary cell free miR-146a and miR-155 in patients with systemic lupus erythematosus. J. Rheumatol. 37, 2516–2522 (2010). · DOI
  71. Wang, G. et al. Urinary miR-21, miR-29, and miR-93, novel biomarkers of fibrosis. Am. J. Nephrol. 36, 412–418 (2012). · DOI
  72. Szeto, C. C. et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 33, 137–144 (2012). · DOI
  73. Wang, G. et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 28, 79–86 (2010). · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Szeto, C.-C., & Li, P. K.-T.
Venue
Nature Reviews Nephrology
Publisher
Springer Science and Business Media LLC
Published
2014-04-08
Volume
10
Issue
5
Pages
249-256
ISSN
  • 1759-5061
  • 1759-507X
DOI
10.1038/nrneph.2014.50
Cited by
80
References
2
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review